Celgene Names Julia A. Haller To Board
This article was originally published in Scrip
Celgene Corp. has appointed Julia A. Haller to its board of directors. Haller is ophthalmologist-in-chief of the Wills Eye Hospital and holds the William Tasman, M.D. endowed chair. She is also professor and chair of the department of ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals and is co-director of the Wills Vision Research Center at Jefferson. Previously Haller was the first female chief resident at the Wilmer Eye Institute at Johns Hopkins and later joined its faculty. She was named the inaugural Katharine Graham professor ophthalmology in 2002 and the inaugural Robert Bond Welch, M.D. professor of ophthalmology in 2006.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.